30 closest matches · ranked by relevance
Non Small Cell Lung Cancer With Bone Metastatses
Primary: Number of Symptomatic Skeletal Events (SSE) in Patients Receiving Xofigo With NSCLC and Bone Metastases — 1 Number of participants experiencing SSE
Lung Cancer
Primary: Order of LDCT — 50 Participants
Non-small Cell Lung Cancer (NSCLC) · Stage IV NSCLC · Metastatic NSCLC
Primary: Objective Response Rate — 0; 1 participants
Non-Small Cell Lung Cancer
Primary: Duration of Treatment of Anti-cancer Drugs — 11; 14; 9.4; 15.8 Months
Lung Cancer
Primary: Median Progression Free Survival (PFS) — 7.5 months
Lung Cancer
Primary: Lung Cancer Deaths — 356; 443 Participants — p=0.004
Lung Cancer
Primary: To Prospectively Collect Data on Chest CT Screening for Patients at Increase Lung-cancer Risk After Hodgkin's Disease. — 0 participants
Non-Small Cell Lung Cancer
Primary: Response Rate — 11 participants
Stage IV Non-small Cell Lung Cancer
Primary: The Study Outcome is Defined as the Systemic Treatment Choice. — 26; 68; 0; 99 Participants
Lung Cancer
Primary: Progression-free Survival — 12.6 months
Lung Cancer · Behavior
Primary: Percentage of Scheduled Lung Cancer Screening Appointments Attended by Participants — 88; 68; 64 % of lcs appointment attendance
Smoking Cessation
Primary: End of Treatment Abstinence Rates — 3; 0 Participants
Non-small Cell Lung Cancer
Primary: Number of Participants With a Change From Baseline in Ventilation Map Using Hyperpolarized Xe-129 MR Imaging — 6 Participants — p=0.041
Non-Small Cell Lung Cancer
Primary: Overall Survival (OS) — 10.9; 10.7 months — p=0.5157
Lung Cancer
Primary: Number of Red Fluorescent [i.e., Cancer] Cells (RFCs) in Sputum From Healthy Participants — 0 number of RFCs per participant
Non-small Cell Lung Cancer
Primary: Percentage of Participants Reporting Quality of Care on Selected National Comprehensive Cancer Center (NCCN) Recommendations — 80; 0; 50; 28.6 percentage of participants
Lung Cancer
Primary: Objective Response Rate (ORR), Presented in Numbers of Participants — 0; 0; 1; 1 Participants
Lung Cancer
Primary: Number of Participants With a Response — 4 Participants — p=0.161
Non-Small-Cell Lung Carcinoma
Primary: Progression-free Survival (PFS) — 5.45; 5.22 months — p=0.848
Lung Cancer
Primary: Changes in VO2peak (on Exercise Capacity) — 17.9; 15.2; 15.2; 14.5 mL/kg/min
Lung Cancer
Primary: 18 Month Survival — 58; 54 percentage of participants
Lung Neoplasms · Carcinoma, Non-small Cell Lung
Primary: Percentage of Participants With Objective Response (OR) — 9.4 Percentage of participants
Non Small Cell Lung Cancer
Primary: Overall Survival — 26.81; 24.97 months — p=0.831
Lung Cancer · Small Cell Lung Cancer · Carcinoma, Non-Small-Cell Lung
Primary: Immune-related Progression-free Survival (irPFS) in Participants With Nonsmall-cell Lung Cancer (NSCLC) Per Immune-related Response Criteria (irRC) — 5.52; 5.68; 4.63…
Thoracic Tumours
Primary: Toxicity Rate of Dose Limiting Toxicities (DLTs) Assessed by CTCAEv4 — 0; 0; 0; 0 Participants
Lung Cancer · Precancerous Condition
Primary: Change in Average (Follow-up - Baseline) From All Biopsies — -0.23; -0.02 WHO Units
Non-Small Cell Lung Cancer
Primary: Time to Progression-Free Survival (PFS) — 7.9 months
Non-small Cell Lung Cancer
Primary: 2-year Disease-free Survival — 88 Participants
Lung Cancer
Primary: Objective Response Rate (ORR) — 7.69 percentage of participants
Non-Small-Cell Lung Carcinoma
Primary: Response Rate — 6 percentage of participants